Istituto Nazionale Tumori IRCCS Fondazione G. Pascale Selects MEVION S250-FIT™ for Southern Italy’s First Proton Therapy Center

The Istituto Nazionale Tumori IRCCS Fondazione G. Pascale in Naples has selected the MEVION S250-FIT proton therapy system to establish Southern Italy’s first proton therapy center. This decision follows a competitive evaluation process and marks a significant advancement in cancer treatment accessibility in the region. The project will be delivered as a turnkey solution through collaboration between Mevion Medical Systems, Leo Cancer Care, and Morveducci, integrating advanced compact proton therapy technology with innovative patient positioning and specialized construction. The MEVION S250-FIT system, which is both U.S. FDA-cleared and CE-marked, addresses traditional barriers to proton therapy adoption in Europe, such as high costs and infrastructure demands. It features HYPERSCAN® pencil-beam scanning technology for Intensity-Modulated Proton Therapy (IMPT) and supports DirectARC™ proton arc therapy, aligning with contemporary radiotherapy workflows. Leo Cancer Care contributes the Marie® Upright Patient Positioning and CT Imaging System, allowing for a compact treatment setup without a conventional rotating gantry. Morveducci will oversee the design and construction of the facility, while RaySearch Laboratories will provide the RayCare® oncology information system and RayStation® treatment planning system to manage clinical workflows and treatment planning. Fondazione Pascale, a leading cancer research and treatment institute recognized by the Italian Ministry of Health, plays a central role in the Campania Oncology Network and is known for integrating translational research with clinical care. The introduction of the MEVION S250-FIT system enhances its capacity to offer cutting-edge proton therapy, which is known for its precision in targeting tumors while minimizing damage to surrounding healthy tissue. This project represents a milestone for Mevion’s European expansion and reflects a broader trend toward more accessible, cost-effective proton therapy solutions worldwide. The MEVION S250-FIT platform has already been adopted by several prominent U.S. cancer centers, and its deployment in Naples signals growing international acceptance of compact proton therapy systems as a viable alternative to traditional, larger-scale proton therapy facilities.